Croissy-Beaubourg, November 18, 2019, 8:00 am CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained the CE marking for its i-Track10 automated analyzer for biotherapy monitoring.

One of the key points of the agreement signed last April with IDS, which manufactures diagnostic test kits and instruments for the clinical market, was the access to their cutting-edge analyzer named
i-Track10.

Manufactured by IDS for Theradiag, this latest generation analyser is the first to be fully compatible with the full range of biotherapy monitoring products. It allows continuous loading, random access analysis and integration into laboratory automation systems.

The CE marking application for i-Track10 is now complete and its market launch has been registered with the French National Drug and Health Product Safety Agency (ANSM).

Internal assessments have confirmed the reliability, flexibility and analyzing speed of the device and independent evaluations have been scheduled to start over the coming weeks.

Feedback from initial presentations to customers and distributors have confirmed the interest and relevance of this unique innovative automated solution.

Theradiag CEO Bertrand de Castelnau commented: “We are delighted to announce the CE marking of this new analyzer as this is a key milestone for Theradiag. Our R&D teams are entirely satisfied with its operation and the quality of the results obtained from our internal assessments. All our technical staff are committed to the success of the project and our entire distribution network is ready for the launch of this innovative product in the first half of 2020.”PR_Theradiag i-Track10 CE Marking VF